-
公开(公告)号：EP4223753A1
公开(公告)日：2023-08-09
申请号：EP21871471.5
申请日：2021-09-22
发明人： ZHOU, Fusheng , JIANG, Tao , LIU, Yingtao , LIN, Chonglan , ZHANG, Leitao , LIU, Zhubo , MA, Kai , HE, Wan , XU, Xiaoming , FENG, Lijian , LAN, Xiaoling , DING, Qian , LV, Qiang , LAN, Jiong
IPC分类号： C07D471/04 , A61K31/437 , A61P29/00
摘要： Disclosed are an aroyl substituted tricyclic compound, a preparation method therefor and use thereof. Specifically, the aroyl substituted tricyclic compound of the present invention has a structure of formula (C), and has, as a BTK inhibitor, the advantages of high activity, good selectivity and low toxic and side effects.
-
公开(公告)号：EP3470409A1
公开(公告)日：2019-04-17
申请号：EP17812617.3
申请日：2017-06-08
发明人： SUN, Fei , WU, Lifang , DING, Charles Z. , HU, Guoping , LI, Jian , CHEN, Shuhui , LU, Jianyu
IPC分类号： C07D401/14 , C07D471/04 , A61K31/4439 , A61K31/4155 , A61P35/00
摘要： A benzotriazole-derived α and β-unsaturated amide compound used as TGF-βR1 inhibitor or a pharmaceutically acceptable salt thereof, the structure of the compound being as shown in formula (I).
-
3.发明公开
公开(公告)号：EP4332105A1
公开(公告)日：2024-03-06
申请号：EP22795037.5
申请日：2022-04-29
发明人： JIANG, Tao , ZHOU, Fusheng , ZHANG, Leitao , CAI, Lijian , XU, Xiaoming , MA, Kai , LIU, Zhubo , LAN, Jiong
IPC分类号： C07D487/08 , C07D519/00 , A61K31/517 , A61K31/5377 , A61P35/00
摘要： Provided is a pyridino- or pyrimido-cyclic compound having an inhibitory effect on a KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein the structure of the compound is as shown in formula (AI) or (AII), and the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition comprising the compound, and the use thereof in the preparation of a cancer drug.
-
4.发明公开
公开(公告)号：EP4053118A1
公开(公告)日：2022-09-07
申请号：EP20882039.9
申请日：2020-10-28
发明人： ZHOU, Fusheng , JIANG, Tao , LIN, Chonglan , CAI, Lijian , HE, Wan , LAN, Jiong
IPC分类号： C07D403/04 , C07D471/00 , A61K31/495 , A61P35/00
摘要： A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs.
-
公开(公告)号：EP3725786A1
公开(公告)日：2020-10-21
申请号：EP18888487.8
申请日：2018-12-13
发明人： WU, Lifang , HE, Huijun , LU, Jianyu , DING, Charles Z. , HU, Lihong , LI, Weidong , SHI, Shenyi , LI, Jian , CHEN, Shuhui
IPC分类号： C07D401/14 , C07D471/04 , A61K31/4155 , A61P35/00 , A61K31/4439
摘要： Disclosed in the present invention are a crystal form and salt form of a TGF-βR1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.
-
6.发明公开
公开(公告)号：EP4328229A3
公开(公告)日：2024-10-02
申请号：EP23204050.1
申请日：2020-10-28
发明人： ZHOU, Fusheng , JIANG, Tao , LIN, Chonglan , CAI, Lijian , HE, Wan , LAN, Jiong
IPC分类号： C07D403/04 , C07D471/00 , A61K31/495 , A61P35/00 , C07D471/14 , C07D471/22 , C07D498/22
CPC分类号： A61P35/00 , C07D471/14 , C07D471/22 , C07D498/22
摘要： A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs.
-
7.发明公开
公开(公告)号：EP4328229A2
公开(公告)日：2024-02-28
申请号：EP23204050.1
申请日：2020-10-28
发明人： ZHOU, Fusheng , JIANG, Tao , LIN, Chonglan , CAI, Lijian , HE, Wan , LAN, Jiong
IPC分类号： C07D498/22
摘要： A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs.
-
公开(公告)号：EP4310091A1
公开(公告)日：2024-01-24
申请号：EP22770598.5
申请日：2022-03-17
发明人： JIANG, Tao , ZHOU, Fusheng , ZHANG, Leitao , CAI, Lijian , YAN, Feng , ZHAO, Jichen , LAN, Jiong , LU, Qiang
IPC分类号： C07D498/14 , C07D471/00 , C07D471/02 , A61K31/55 , A61P35/00
摘要： Disclosed are a pyrimidine-fused cyclic compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating cancer.
-
9.发明公开
公开(公告)号：EP3943488A1
公开(公告)日：2022-01-26
申请号：EP20777468.8
申请日：2020-03-20
发明人： ZHOU, Fusheng , XU, Xiaoming , ZHANG, Leitao , LIU, Zhubo , HU, Gang , DING, Qian , XIE, Fubo , ZHENG, Biao , LV, Qiang , LAN, Jiong
IPC分类号： C07D277/82 , C07D471/04 , A61K31/428 , A61K31/437 , A61P31/00
摘要： Provided are a substituted heterocyclic amide compound having a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use of same in the preparation of a drug for treating a RIPK1-related diseases or conditions.
-
10.发明公开
公开(公告)号：EP4382528A1
公开(公告)日：2024-06-12
申请号：EP22852140.7
申请日：2022-08-02
发明人： ZHOU, Fusheng , TAO, Yuanzhi , ZHAO, Jinzhu , LAN, Jiong
IPC分类号： C07D471/04 , C07D401/14 , A61K31/4353 , A61K31/4375 , A61P31/00
CPC分类号： C07D401/14 , A61P31/00 , A61K31/4375 , A61K31/4353 , C07D471/04
摘要： Disclosed are a crystal form of a RIPK1 inhibitor, an acid salt thereof, and a crystal form of an acid salt thereof. The crystal form of the RIPK1 inhibitor, the acid salt thereof, and the crystal form of the acid salt thereof have advantages of good stability and low hygroscopicity, and same have good pharmaceutical prospects.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.016 秒)
